Blocking interleukin-6 activity with chimeric Anti-IL6 monoclonal antibodies in multiple myeloma: Effects on soluble IL6 receptor and soluble gp130

Leukemia and Lymphoma

Volumn 31, Issue 5-6, 1998, Pages 551-558

  Van Zaanen, H C T ^a,e   Lokhorst, H M ^b   Aarden, L A ^c   Rensink, H J A M ^c   Warnaar, S O ^d   Van Oers, M H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Academic Hospital Utrecht   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d Centocor   (Netherlands)

^e Dep of Internal Medicine   (Netherlands)

Author keywords

Anti IL6 Mab; Multiple myeloma; Soluble gp130; Soluble IL6R

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA;

EID: 0032466601     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057614     Document Type: Article

References (39)

1. Kishimoto, T., Akira, S. and Taga, T. (1992) IL-6 and its receptor: A paradigm for cytokines. Science, 258, 593-597.
2. Yamasaki, K., Taga, T., Hirata, Y., Yawaka, H., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T. and Kishimoto, T. (1988) Cloning and expression of the human IL-6 (BSF-2/IFN b2) receptor. Science, 241, 825-828.
3. Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T. and Kishimoto, T. (1989) IL-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58, 573-581.
4. Kishimoto, T., Akira, S., Narazaki, M. and Taga, T. (1995) IL-6 family of cytokines and gp130. Blood, 86, 1243-1254.
5. Klein, B., Zhang, X.G., Lu, Z.Y. and Bataille, R. (1995) IL-6 in human multiple myeloma. Blood, 85, 863-872.
6. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishi-hara, Y., Yancopoulos, G., Taga, T. and Kishimoto, T. (1993) Soluble forms of the IL-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood, 82, 1120-1126.
7. Lust, J., Donovan, K., Kline, M., Greipp, P., Kyle, R. and Maihle, N. (1992) Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine, 4, 96-100.
8. Mullberg, J., Schooltink, H., Stoyan, T., Gunther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P. and Rose-John, S. (1993) The soluble IL-6 receptor is generated by shedding. European Journal of Immunology, 23, 473-480.
9. Rose-John, S. and Heinrich, P. (1994) Soluble receptors for cytokines and growth factors: generation and biological function (review). Biochemical Journal, 300, 281-290.
10. Anderson, K., Jones, R., Morimoto, C., Leavitt, P. and Barut, B. (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood, 73, 1915-1924.
11. Bataille, R., Jourdan, M., Zhang, XG., and Klein, B. (1989) Serum levels of IL6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
12. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanaka, H., Kuramoto, A. and Kishimoto, T. (1988) Autocrine generation and requirement of BSF 2/IL6 for human multiple myelomas. Nature, 332, 83-85.
13. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, J., Aarden, L.A., Piechaczyk, M. and Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by IL6. Blood, 73, 517-526.
14. Klein, B., Zhang, X.G., Jourdan, M., Boiron, J., Portier, M., Lu, Z., Wijdenes, J., Brochier, J. and Bataille, R. (1990) IL6 is the central tumor growth factor in vitro and in vivo in multiple myeloma (review). European Cytokine Network, 1, 193-201.
15. Nordan, R., Pumphrey, J. and Rudikoff, S. (1987) Purification and NH2-terminal sequence of a plasmacytoma growth-factor derived from the murine macrophage cell line P 388 D1. Journal of Immunology, 139, 813-817.
16. Van Oers, M.H.J., van Zaanen, H.C.T. and Lokhorst, H.M. (1993) Interleukin-6, a new target for therapy in multiple myeloma? (review). Annals of Hematology, 66, 219-223.
17. Zhang, X.G., Klein, B. and Bataille, R. (1989) IL6 is a potent myeloma cell growth factor in patients with aggressive MM. Blood, 74, 11-13.
18. Gaillard, J.P., Bataille, R., Brailly, H., Zuber, C., Yasukawa, K., Attal, M., Maruo, N., Taga, T., Kishimoto, T. and Klein, B. (1993) Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. European Journal of Immunology, 23, 820-824.
19. Pulkki, K., Pelliniemi, T.T., Rajamaki, A., Tienhaara, A., Laakso, M. and Lahtinen, R. (1996) Soluble IL-6 receptor as a prognostic factor in multiple myeloma. British Journal of Haematology, 92, 370-374.
20. Portier, M., Lees, D., Caron, E., Jourdan, M., Boiron, J.M., Bataille, R. and Klein, B. (1992) Up-regulation of IL-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells. FEBS letters, 302, 35-38.
21. Durie, B. and Salmon, S. (1977) Multiple myeloma, macroglobulinemia and monoclonal gammopathie. In Recent advances in haematology, edited by A.V. Hoffbrand, M.C. Brown and J. Hirsch. pp 243-261. Churchill Livingstone, Edinburgh.
22. Brakenhoff, J., Hart, M., de Groot, E., Di Padova, F. and Aarden, L.A. (1990) Structure-function analysis of human IL6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. Journal of Immunology, 145, 561-568.
23. Ehlers, M., Grotzinger, J., de Hon, F., Mullberg, J., Brakenhoff, J., Liu, J., Wollmer, A. and Rose-John, S. (1994) Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. Journal of Immunology, 153, 1744-1751.
24. Van Zaanen, H.C.T., Koopmans, R.P., Aarden, L.A., Rensink, H.J., Stouthard, J., Warnaar, S.O., Lokhorst, H.M. and van Oers, M.H.J. (1996) Endogenous IL6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed back loop. Journal of Clinical Investigation, 98, 1441-1448.
25. Aarden, L.A., de Groot, E., Schaap, O. and Lansdorp, P. (1987) Production of hybridoma growth factor by human monocytes. European Journal of Immunology, 17, 1411-1416.
26. Aarden, L. (1991) Plasmacytomas. In Mechanisms of B cell neoplasm, edited by F. Melchens and M. Potter. pp 429-433, Editione Roche, Basel, Switzerland.
27. Van Zaanen, H.C.T., Lokhorst, H.M., Aarden, L.A., Rensink, H.J., Warnaar, S.O. and van Oers, M.H.J. (1994) Phase I/II multiple-dose pilot study of chimeric anti-IL6 monoclonal antibodies in multiple myeloma (Abstr.). British Journal of Haematology, 87, Suppl. I, 238.
28. Honda, M., Yamamoto, S., Cheng, M., Yasukawa, K., Suzuki, H., Saito, T., Osugi, Y., Tokunaga, T. and Kishimoto, T. (1992) Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. Journal of Immunology, 148, 2175-2180.
29. Yokoyama, A., Kohno, N., Hirasawa, Y., Kondo, K., Abe, M., Inoue, Y., Fujioka, S., Fujino, S., Ishida, S. and Hiwada, K. (1995) Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clinical Experimental Immunology, 100, 325-329.
30. Ohtani, K., Ninomiya, H., Hasegawa, Y., Kobayashi, T., Kojima, H., Nagasawa, T. and Abe, T. (1995) Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscraias. British Journal of Haematology, 91, 116-120.
31. Kyrtsonis, M., Dedoussis, G., Zervas, C., Perifanis, V., Baxevanis, C., Stamatelou, M. and Maniatis, A. (1996) Soluble interleukin-6 receptor, a new prognostic factor in multiple myeloma. British Journal of Haematology, 93, 398-400.
32. Smith, S. and Morgan, L. (1996) Clinical significance of elevated soluble interleukin 6 receptor levels in patients with plasma cell disorders. British Journal of Haematology, 92, 766-773.(letter).
33. Kang, H., Lee, B., Yang Y., Park, C., Ha, H., Pyun, K. and Choi, I. (1996) Roles of protein phosphatase 1 and 2A in an IL6-mediated autocrine growth loop of human myeloma cells. Cellular Immunology, 168, 174-183.
34. Heinrich, P., Castell, J. and Andus, T. (1990) IL6 and the acute phase response (review). Biochemical Journal, 265, 621-636.
35. Coulie, P.G., Stevens, M. and Van Snick, J. (1989) High- and low-affinity receptors for murine interleukin 6. Distinct distribution on B and T cells. European Journal of Immunology, 19, 2107-2114.
36. Tura, S. and Cavo, M. (1992) Allogeneic bone marrow transplantation in multiple myeloma. In Hematology/oncology clinics of North America, edited by B. Barlogie, page 433. W.B. Saunders Company, Philadelphia, USA.
37. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T. and Kishimoto, T. (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell, 63, 1149-1157.
38. Lokhorst, H.M., Lamme, T., de Smet, M., Klein, S., de Weger, R., van Oers, M.H.J. and Bloem, A. (1994) Primary tumor cells of myeloma patients induce IL6 secretion in long-term bone marrow cultures. Blood, 84, 2269-2277.
39. Bellido, T., Stahl, N., Farruggella, T., Borba, V., Yancopoulos, G. and Manolagas, C. (1996) Detection of receptors for interleukin-6, interleukin-11, LIF, Oncostatin M, and CNTF in bone marrow stromal/ osteoblastic cells. Journal of Clinical Investigation, 97, 431-437.